Indivior (INDV) Scheduled to Post Earnings on Thursday

Indivior (NASDAQ:INDV) is scheduled to be posting its quarterly earnings results before the market opens on Thursday, April 25th. Analysts expect Indivior to post earnings of $0.38 per share for the quarter. Indivior has set its FY 2024 guidance at EPS.

Indivior (NASDAQ:INDV) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.15. Indivior had a return on equity of 538.18% and a net margin of 0.18%. The business had revenue of $293.00 million for the quarter, compared to analysts’ expectations of $260.00 million. On average, analysts expect Indivior to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Indivior Stock Down 0.7 %

Shares of INDV opened at $19.26 on Thursday. The business’s 50 day moving average price is $20.41 and its 200-day moving average price is $18.42. Indivior has a 52 week low of $14.38 and a 52 week high of $26.50. The stock has a market cap of $2.66 billion, a P/E ratio of -962.52 and a beta of 0.46.

Wall Street Analyst Weigh In

Separately, Craig Hallum began coverage on Indivior in a research report on Wednesday, April 3rd. They issued a “buy” rating and a $37.00 price objective on the stock.

Institutional Investors Weigh In On Indivior

Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Indivior by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 5,899,190 shares of the company’s stock worth $90,081,000 after buying an additional 52,836 shares in the last quarter. Goldman Sachs Group Inc. purchased a new position in shares of Indivior during the second quarter worth approximately $83,678,000. Barclays PLC increased its position in shares of Indivior by 746.6% during the fourth quarter. Barclays PLC now owns 3,093,161 shares of the company’s stock worth $47,232,000 after acquiring an additional 2,727,791 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its holdings in Indivior by 53.6% during the fourth quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 176,976 shares of the company’s stock valued at $2,673,000 after buying an additional 61,772 shares during the period. Finally, Deutsche Bank AG purchased a new position in Indivior during the third quarter valued at approximately $3,181,000. 60.33% of the stock is currently owned by hedge funds and other institutional investors.

About Indivior

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.